마티나스 바이오파마 홀딩스(MTNB)는 NYSE MKT에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.16 (+0.49%), 시가총액 $0.00B, 52주 최저~최고 $0.49 ~ $2.36.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The
마티나스 바이오파마 홀딩스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
마티나스 바이오파마 홀딩스의 현재 주가는 $0.16 (+0.49%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
마티나스 바이오파마 홀딩스의 시가총액은 약 $0.00B입니다.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC d